EUVIMEDEUVIMED entdecken
Crossref

Abstract 75: RAAS Biomarker Profiles and Treatment Response to Renal Artery Stenting in Atherosclerotic Renal Artery Stenosis: A Post Hoc Analysis of CORAL

Devon Gaur, Mario R Funes Hernandez, Sachin Pasricha, Jia Wei Tan, Robert Isom, Glenn M Chertow, Marko Poglitsch, Steven Haller, Christopher J Cooper, Robin C Shoemaker, Vivek Bhalla

Hypertension · 2026-10 · 83 (Suppl_1)

DOI: 10.1161/hyp.83.suppl_1.75 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Devon Gaur und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with renal artery stenosis, the CORAL trial found no significant benefits of renal artery stenting compared to medical therapy alone for the primary composite endpoint of cardiovascular death, stroke, myocardial infarction, hospitalization for heart failure, progressive renal insufficiency, or need for renal replacement therapy. Whether baseline renin-angiotensin-aldosterone system (RAAS) phenotypes modified treatment response remains unknown. We hypothesized that renin-independent aldosteronism increases risk for major cardiovascular and kidney events and would attenuate the benefits of renal artery stenting over medical therapy. Baseline RAAS biomarkers, including angiotensin I (Ang I), angiotensin II (Ang II), and aldosterone were measured by mass spectrometry in pmol/L and analyzed against the primary composite endpoint. Participants were stratified into tertiles of aldosterone, renin activity (Ang I + Ang II), aldosterone-to-angiotensin II ratio (AA2R) or aldosterone-to-renin ratio (ARR). We analyzed data on 762/947 (80%) patients with available baseline RAAS biomarker samples. Baseline characteristics were not significantly different between the biomarker vs. the full trial cohort, nor across tertiles of individual biomarker indices. Treatment effect varied significantly by aldosterone tertile (interaction p=0.01). Stenting plus medical therapy (compared with medical therapy alone) was associated with a lower risk of the primary composite endpoint in the lowest tertile of serum aldosterone compared with medical therapy alone (HR 0.52, 95% CI 0.35-0.77; p3.15) or ARR (>0.78) tertiles were excluded, event-free survival was significantly improved with stenting (p=0.02) (Figure 3). In this post-hoc analysis of CORAL, RAAS phenotypes significantly modified treatment response to renal artery stenting. Benefit was observed predominantly in patients with low baseline aldosterone and/or high renin activity. The absence of renin-independent aldosterone excess, identified by lower AA2R or ARR, may identify patients more likely to benefit from renal revascularization, though prospective validation is warranted.

Zitieren

APA

Gaur, D., Hernandez, M. R. F., Pasricha, S., Tan, J. W., Isom, R., Chertow, G. M., Poglitsch, M., Haller, S., Cooper, C. J., Shoemaker, R. C., & Bhalla, V. (2026). Abstract 75: RAAS Biomarker Profiles and Treatment Response to Renal Artery Stenting in Atherosclerotic Renal Artery Stenosis: A Post Hoc Analysis of CORAL. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.75

Vancouver

Gaur D, Hernandez MRF, Pasricha S, Tan JW, Isom R, Chertow GM, et al. Abstract 75: RAAS Biomarker Profiles and Treatment Response to Renal Artery Stenting in Atherosclerotic Renal Artery Stenosis: A Post Hoc Analysis of CORAL. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.75

BibTeX
@article{Gaur2026,
  author = {Gaur, Devon and Hernandez, Mario R Funes and Pasricha, Sachin and Tan, Jia Wei and Isom, Robert and Chertow, Glenn M and Poglitsch, Marko and Haller, Steven and Cooper, Christopher J and Shoemaker, Robin C and Bhalla, Vivek},
  title = {Abstract 75: RAAS Biomarker Profiles and Treatment Response to Renal Artery Stenting in Atherosclerotic Renal Artery Stenosis: A Post Hoc Analysis of CORAL},
  journal = {Hypertension},
  year = {2026},
  volume = {83},
  number = {Suppl_1},
  doi = {10.1161/hyp.83.suppl_1.75}
}
Kostenlos starten →